Blueprint Medicines Corp at Stifel Targeted Oncology Days (Virtual) Transcript
Hey. I'm Brad Canino, senior analyst here at Stifel. Thanks again for joining us on our first day of the targeted oncology days we're hosting here across several of my analyst colleagues. Happy to continue the fireside chat sessions here with Blueprint. I'm really delighted to have Percy Carter, Chief Scientific Officer; Fouad Namouni, the President, Research & Development. Thank you both for joining us today.
Thank you, Brad. Happy to be here.
Questions & Answers
I think we're going to keep this conversation pretty asset focused in line with the theme of the event as well. No, questions on ISM, but I'm sure there's a lot of transcripts even from some Stifel conferences recently that cover a lot of those questions. So, on the oncology franchise, I'll start with BLU-945 for frontline EGFR-mutant non-small cell lung cancer.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |